Active, not recruitingPhase 4NCT05118490

Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

Studying Primary genito-urinary tuberculosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Aurum Institute NPC
Principal Investigator
Gavin Churchyard
Aurum Institute
Intervention
Daily rifapentine and isoniazid for 4 weeks(drug)
Enrollment
1000 enrolled
Eligibility
13 years · All sexes
Timeline
2023 – 2025

Study locations (4)

Collaborators

Johns Hopkins University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05118490 on ClinicalTrials.gov

Other trials for Primary genito-urinary tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Primary genito-urinary tuberculosis →

← Back to all trials